MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$13,783,232
EPS
-$0.21
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-31
2025-09-30
2025-06-30
Research and development
10,645,222
10,867,983
10,454,160
General and administrative
4,682,495
4,505,406
4,296,417
Amortization of intangible asset
7,317
7,317
7,317
Total operating expenses
15,335,034
15,380,706
14,757,894
Loss from operations
-15,335,034
-15,380,706
-14,757,894
Interest income
1,360,404
415,831
324,013
Other income, net
513,735
0
0
Net loss
-13,460,895
-14,964,875
-14,433,881
Unrealized loss from marketable securities
-322,337
0
0
Comprehensive loss
-13,783,232
-14,964,875
-14,433,881
Basic EPS
-0.21
-0.38
-0.4
Diluted EPS
-0.21
-0.38
-0.4
Basic Average Shares
64,658,809
39,670,095
35,985,878
Diluted Average Shares
64,658,809
39,670,095
35,985,878
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$13,783,232
Net loss
-$13,460,895
Unrealized loss from
marketable securities
-$322,337
Interest income
$1,360,404
Other income, net
$513,735
Loss from operations
-$15,335,034
Total operating
expenses
$15,335,034
Research and development
$10,645,222
General and
administrative
$4,682,495
Amortization of intangible
asset
$7,317
Buy us a coffee
Immuneering Corp (IMRX)
Immuneering Corp (IMRX)